Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?

Laura E. Finn, James M Foran

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose of review Despite the fact that acute myeloid leukemia (AML) is most common in older adults aged at least 60 years, curative therapy remains elusive in this population. Here we examine the data for predicting which patients are candidates for 'curative therapy', available therapeutic options, and the utilization of reduced intensity allogeneic stem cell transplantation in first remission. Recent findings Incorporation of geriatric assessment tools to assess patient frailty, in addition to evaluation of comorbid conditions, improves patient selection for intense therapy. The majority of patients eligible for and treated with induction chemotherapy achieve complete remission, and overall survival in the older AML population is superior after allogeneic stem cell transplant. However, population-based studies continue to demonstrate the undertreatment or lack of treatment of older AML patients. Summary New patient assessment tools, ability to offer more successful outcomes after induction chemotherapy, and improved survival after allogeneic transplantation has not yet translated to increased 'curative' treatment on a population level of older AML patients. It is critical that the tools and therapies available be put into practice while older patient enrollment in well designed therapeutic clinical trials which include the option of allogeneic transplantation is increased.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalCurrent Opinion in Hematology
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Homologous Transplantation
Acute Myeloid Leukemia
Induction Chemotherapy
Therapeutics
Population
Geriatric Assessment
Survival
Stem Cell Transplantation
Patient Selection
Stem Cells
Clinical Trials
Transplants

Keywords

  • acute myeloid leukemia
  • allogeneic stem cell transplant
  • complete remission
  • frailty
  • induction chemotherapy

ASJC Scopus subject areas

  • Hematology

Cite this

Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1? / Finn, Laura E.; Foran, James M.

In: Current Opinion in Hematology, Vol. 23, No. 2, 01.03.2016, p. 95-101.

Research output: Contribution to journalArticle

@article{df46afea23c6499cb88faa106f2ec35e,
title = "Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?",
abstract = "Purpose of review Despite the fact that acute myeloid leukemia (AML) is most common in older adults aged at least 60 years, curative therapy remains elusive in this population. Here we examine the data for predicting which patients are candidates for 'curative therapy', available therapeutic options, and the utilization of reduced intensity allogeneic stem cell transplantation in first remission. Recent findings Incorporation of geriatric assessment tools to assess patient frailty, in addition to evaluation of comorbid conditions, improves patient selection for intense therapy. The majority of patients eligible for and treated with induction chemotherapy achieve complete remission, and overall survival in the older AML population is superior after allogeneic stem cell transplant. However, population-based studies continue to demonstrate the undertreatment or lack of treatment of older AML patients. Summary New patient assessment tools, ability to offer more successful outcomes after induction chemotherapy, and improved survival after allogeneic transplantation has not yet translated to increased 'curative' treatment on a population level of older AML patients. It is critical that the tools and therapies available be put into practice while older patient enrollment in well designed therapeutic clinical trials which include the option of allogeneic transplantation is increased.",
keywords = "acute myeloid leukemia, allogeneic stem cell transplant, complete remission, frailty, induction chemotherapy",
author = "Finn, {Laura E.} and Foran, {James M}",
year = "2016",
month = "3",
day = "1",
doi = "10.1097/MOH.0000000000000220",
language = "English (US)",
volume = "23",
pages = "95--101",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?

AU - Finn, Laura E.

AU - Foran, James M

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose of review Despite the fact that acute myeloid leukemia (AML) is most common in older adults aged at least 60 years, curative therapy remains elusive in this population. Here we examine the data for predicting which patients are candidates for 'curative therapy', available therapeutic options, and the utilization of reduced intensity allogeneic stem cell transplantation in first remission. Recent findings Incorporation of geriatric assessment tools to assess patient frailty, in addition to evaluation of comorbid conditions, improves patient selection for intense therapy. The majority of patients eligible for and treated with induction chemotherapy achieve complete remission, and overall survival in the older AML population is superior after allogeneic stem cell transplant. However, population-based studies continue to demonstrate the undertreatment or lack of treatment of older AML patients. Summary New patient assessment tools, ability to offer more successful outcomes after induction chemotherapy, and improved survival after allogeneic transplantation has not yet translated to increased 'curative' treatment on a population level of older AML patients. It is critical that the tools and therapies available be put into practice while older patient enrollment in well designed therapeutic clinical trials which include the option of allogeneic transplantation is increased.

AB - Purpose of review Despite the fact that acute myeloid leukemia (AML) is most common in older adults aged at least 60 years, curative therapy remains elusive in this population. Here we examine the data for predicting which patients are candidates for 'curative therapy', available therapeutic options, and the utilization of reduced intensity allogeneic stem cell transplantation in first remission. Recent findings Incorporation of geriatric assessment tools to assess patient frailty, in addition to evaluation of comorbid conditions, improves patient selection for intense therapy. The majority of patients eligible for and treated with induction chemotherapy achieve complete remission, and overall survival in the older AML population is superior after allogeneic stem cell transplant. However, population-based studies continue to demonstrate the undertreatment or lack of treatment of older AML patients. Summary New patient assessment tools, ability to offer more successful outcomes after induction chemotherapy, and improved survival after allogeneic transplantation has not yet translated to increased 'curative' treatment on a population level of older AML patients. It is critical that the tools and therapies available be put into practice while older patient enrollment in well designed therapeutic clinical trials which include the option of allogeneic transplantation is increased.

KW - acute myeloid leukemia

KW - allogeneic stem cell transplant

KW - complete remission

KW - frailty

KW - induction chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84957434595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957434595&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000220

DO - 10.1097/MOH.0000000000000220

M3 - Article

VL - 23

SP - 95

EP - 101

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -